Literature DB >> 16215410

Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial.

Peter Q Eichacker, Robert L Danner, Anthony F Suffredini, Xizhong Cui, Charles Natanson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16215410     DOI: 10.1097/01.ccm.0000183002.26587.ff

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


× No keyword cloud information.
  16 in total

1.  An update on activated protein C (xigris) in the management of sepsis.

Authors:  Cesar Alaniz
Journal:  P T       Date:  2010-09

2.  Evaluation of drotrecogin alpha use in a Belgian university hospital.

Authors:  Isabel Spriet; Wouter Meersseman; Alexander Wilmer; Geert Meyfroidt; Minne Casteels; Ludo Willems
Journal:  Pharm World Sci       Date:  2006-11-17

3.  When a single pivotal trial should not be enough-the case of drotrecogin-alfa (activated).

Authors:  Christian J Wiedermann
Journal:  Intensive Care Med       Date:  2006-03-01       Impact factor: 17.440

4.  Increasing evidence that the risks of rhAPC may outweigh its benefits.

Authors:  Peter Q Eichacker; Charles Natanson
Journal:  Intensive Care Med       Date:  2007-02-15       Impact factor: 17.440

5.  [Endogenous anticoagulant therapy for sepsis. Success and failure].

Authors:  C J Wiedermann
Journal:  Internist (Berl)       Date:  2007-05       Impact factor: 0.743

6.  Mechanisms of sepsis and insights from clinical trials.

Authors:  Nitin Seam; Anthony F Suffredini
Journal:  Drug Discov Today Dis Mech       Date:  2007

7.  Editors' comments on a new trial of activated protein C for persistent septic shock.

Authors:  Jordi Mancebo; Massimo Antonelli
Journal:  Intensive Care Med       Date:  2008-10-07       Impact factor: 17.440

8.  How many patients with severe sepsis are needed to confirm the efficacy of drotrecogin alfa activated? A Bayesian design.

Authors:  Andre C Kalil; Junfeng Sun
Journal:  Intensive Care Med       Date:  2008-05-27       Impact factor: 17.440

9.  Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies.

Authors:  Laith Altaweel; Daniel Sweeney; Xizhong Cui; Amisha Barochia; Charles Natanson; Peter Q Eichacker
Journal:  Biologics       Date:  2009-09-15

10.  Role of clinical evaluation committees in sepsis trials: from 'valid cohort' assessment to subgroup analysis.

Authors:  Jean-François Dhainaut
Journal:  Crit Care       Date:  2009-03-18       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.